Advertise With Us
News

Adlai Nortye prices Nasdaq IPO, raises $97.5M

The Nasdaq is welcoming another company hustling along a late-stage drug, with Adlai Nortye raising $97.5 million from an IPO and a concurrent private placement. Adlai Nortye licensed its lead program, the PI3K inhibitor buparlisib, […]

Advertise With Us
Advertise With Us